ESLAW - Estrella Immunopharma Inc - Warrants (29/09/2028)
Previous close
0.1
0 0%
Share volume: 2,000
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.10
0.00
0.00%
Summary score
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Long-term ratios 30-Jun-2016 - 30-Jun-2020
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over timeo
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Short-term ratios 30-Jun-2019 - 30-Jun-2020
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over timeo
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Last quarter ratios 30-Jun-2020
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over time
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Performance ratios (change over 4 years) 30-Jun-2016 - 30-Jun-2020
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over time
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | ESLAW | ABBV | AMGN | REGN |
|---|---|---|---|---|
| Return on equity | 0% | -3.05% | 11.55% | 6.27% |
| Return on assets | 0% | 3.6% | 3.57% | 5.27% |
| Return on sales | 0% | 32.14% | 42.16% | 33.08% |
| Return on invested capital | 0% | 5.09% | 7.99% | 13.19% |
| Profitability | 0% | 46% | 82% | 83% |
| Total debt ratio | 0% | 101.18% | 74.11% | 29.58% |
| Debt ratio change over time | 0% | 6.09% | 6.03% | 1.53% |
| Dept financing | 0% | 50% | 43% | 14% |
| Current Ratio | 0% | 2.08% | 2.02% | 3.51% |
| Quick Ratio | 0% | 1.96% | 1.71% | 2.86% |
| Cash Position Ratio | 0% | 1.48% | 0.76% | 1.49% |
| Liquididy | 0% | 35% | 61% | 73% |
| Short-term ratios | ESLAW | ABBV | AMGN | REGN |
|---|---|---|---|---|
| Return on equity | 0% | -25.62% | 17.94% | 7.14% |
| Return on assets | 0% | 3.26% | 3.67% | 4.71% |
| Return on sales | 0% | 31.22% | 37.5% | 33.58% |
| Return on invested capital | 0% | 8.14% | 7.17% | 18.16% |
| Profitability | 0% | 49% | 79% | 82% |
| Total debt ratio | 0% | 105.33% | 83.42% | 27.49% |
| Debt ratio change over time | 0% | -23.44% | 9.66% | 0.6% |
| Dept financing | 0% | 25% | 45% | 8% |
| Current Ratio | 0% | 2.08% | 2.02% | 3.51% |
| Quick Ratio | 0% | 1.96% | 1.71% | 2.86% |
| Cash Position Ratio | 0% | 1.48% | 0.76% | 1.49% |
| Liquididy | 0% | 57% | 42% | 75% |